北京若生智能科技有限公司
Drug Database
FL

fluticasone propionate

✓ Approved

Cantabria Labs · NR3C1 · 小分子

什么是 fluticasone propionate？

fluticasone propionate 是一种小分子，由Cantabria Labs研发。该药已获批，用于治疗相关适应症，给药途径：Topical。

药物档案

公司Cantabria Labs
药物类别小分子
分子靶点NR3C1
给药途径Topical
状态Approved
来源： ClinicalTrials.gov, Cantabria Labs

作用机制

分子靶点

fluticasone propionate 作用于 1 个分子靶点：

NR3C1nuclear receptor subfamily 3 group C member 1 (GR, GCCR)
需要更深入的分析？Noah AI 可解释复杂机制并与同类药物比较。

治疗适应症

fluticasone propionate 针对 1 个适应症，涉及 1 个治疗领域。

治疗领域疾病/病症分期
InvestigationsDermatologic examination✓ Approved

相关研究文献

PubMedClinical case reports2026-10-27

Vehicle Optimization of Topical Clobetasol Propionate in Disseminated Granuloma Annulare: Clinical Insights From Two Cases.

Meduri Alexandre Raphael AR, Sbarra Giorgia G, Ciccarese Giulia G, Danza Paolo P et al.

Vehicle composition may influence topical corticosteroid performance. In two patients with disseminated granuloma annulare, switching from clobetasol ointment to the same-strength solution in diethylene glycol monoethyl ether (DEGEE) was followed by complete clearance, suggesting formulation optimization may be considered when topical treatment provides an inadequate response.

PMID 42936453
阅读全文 →
PubMedJournal of clinical medicine2026-10-27

Real-World Effects of Single-Inhaler Fluticasone Furoate/Umeclidinium/Vilanterol in Chinese Patients with Asthma.

Li Anqi A, Pan Zhouxian Z, Liu Juan J, Li Lun L et al.

Background/Objectives: Asthma is a heterogeneous chronic inflammatory airway disease. In China, achieving rapid asthma control remains a major challenge, and a substantial proportion of patients remain inadequately controlled despite regular use of standard inhaled corticosteroid/long-acting β2-agonist (ICS/LABA) therapy. Fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI) has demonstrated clinical efficacy in trials, but its real-world effectiveness and safety in China remain insufficiently characterized. This study evaluated FF/UMEC/VI (100/62.5/25 μg) in Chinese patients with uncontrolled asthma. Methods: This retrospective study included patients with asthma treated with FF/UMEC/VI at the Department of Allergy, Peking Union Medical College Hospital, between July 2021 and March 2024. The cohort included patients with no prior inhaled medication, irregular prior inhaled therapy, or regular prior inhaled therapy with inadequate control, reflecting a real-world spectrum of patients requiring treatment intensification. Assessments were performed at baseline and 1, 3, and 6 months after treatment initiation. The primary endpoint was the change in forced expiratory volume in 1 s (FEV1) at 1 month. Secondary outcomes included changes in FEV1, percent predicted FEV1, and FEV1/forced vital capacity (FEV1/FVC), and safety. Results: Thirty patients were analyzed. FEV1 increased significantly at 1 month and remained above baseline at 3 and 6 months. Percent predicted FEV1 and FEV1/FVC also improved significantly at all follow-up visits. Maintenance therapy was reduced in 53.3% of patients. No serious adverse events occurred; reported events were mainly local throat discomfort and increased sputum production. Conclusions: In real-world practice, FF/UMEC/VI was associated with improved lung function measures in Chinese patients, including previously untreated, irregularly treated, and regularly treated but uncontrolled patients, with an acceptable safety profile. Larger prospective studies are warranted to confirm its long-term effectiveness and identify appropriate patient populations in China.

PMID 42941503
阅读全文 →
PubMedVeterinary sciences2026-10-27

Dose-Related Associations of a Palm Kernel Meal-Derived Mannan-Oligosaccharide-Containing Hydrolysate with Selected Immune and Ruminal Fermentation Measures in Growing Goats.

Roekngam Natthrit N, Chuchai Supinya S, Thongmanee Porntip P, Thongtem Niramol N et al.

Mannan-oligosaccharides (MOS) may influence microbial and immune-related processes, but evidence concerning palm kernel meal (PKM)-derived MOS-containing products in goats remains limited. The experimental product was a chemically heterogeneous PKM-derived hydrolysate in which M2-M6 oligosaccharides were identified by HPLC-RID; residual sugars and other soluble constituents were also present. Twenty growing male goats received 0, 2.5, 5.0, or 10.0 g hydrolysate/goat/day (n = 5 per treatment) for 90 days. Feed intake, growth, hematological and serum biochemical indices, circulating immune indicators, peripheral blood leukocyte gene expression, and selected ruminal measures were evaluated. Immune and gene-expression outcomes were measured in prefeeding blood collected on Day 90. Ruminal pH and acetate, propionate, and butyrate were measured in a single rumen-fluid sample collected 3 h after feeding on Day 90. Serum IgA showed a positive linear association with supplementation level, whereas IL-1β and IL-6 showed negative associations; these remained significant after false-discovery-rate correction (q = 0.036, 0.012, and 0.012, respectively). Selected immune-related transcripts also differed among treatments, but these endpoint patterns do not establish coordinated immunological regulation or a specific mechanism. Propionate and butyrate showed nominal positive linear associations, whereas the acetate-to-propionate ratio showed a nominal negative association (raw p = 0.028, 0.021, and 0.018, respectively); none remained significant after correction (q = 0.056 for each). Ruminal pH, the sum of the three measured VFA concentrations, feed intake, and growth did not differ detectably. No overt clinical abnormalities requiring veterinary intervention were observed, but the study was not powered to establish safety. These preliminary between-group endpoint associations concern the complete heterogeneous hydrolysate and cannot be attributed specifically to M2-M6 oligosaccharides. Larger, adequately powered studies with pretreatment and repeated measurements are required.

PMID 42944104
阅读全文 →
PubMedPlants (Basel, Switzerland)2026-10-27

Effects of Lindera aggregata Linderae Radix on Testosterone Propionate-Induced Benign Prostatic Hyperplasia in Rats.

Kang Sehwang S, An Sueyoung S, Yoo Mi-Hyang MH, Gao Enmei E et al.

Linderae Radix, the root of Lindera aggregata, has shown beneficial effects on bladder function in experimental studies, but whether it can attenuate benign prostatic hyperplasia (BPH) remains unknown. This study evaluated an ethanol extract of L. aggregata roots (LAE) in a testosterone propionate (TP)-induced rat model of prostatic hyperplasia. Castrated male Sprague-Dawley rats received TP (3 mg/kg/day, subcutaneously) and LAE (200 mg/kg/day) or finasteride (1 mg/kg/day) orally for 14 days. LAE significantly reduced total and ventral prostate weights and indices, together with ventral prostate histological scores and epithelial thickness. The serum dihydrotestosterone/testosterone ratio was significantly lower in the LAE group than in the control group. In the ventral prostate, aromatase protein expression was significantly reduced by LAE treatment. Significant changes in apoptosis-related proteins included increased Bax and cleaved caspase-3 levels, decreased procaspase-9 levels, and higher cleaved/procaspase ratios of both caspases. These findings demonstrate that LAE attenuated TP-induced prostatic hyperplasia in rats. The accompanying hormonal and protein expression changes provide a basis for further mechanistic investigation. Further evaluation of LAE as a potential therapeutic option for BPH is warranted.

PMID 42943155
阅读全文 →
PubMedMicroorganisms2026-10-27

Effects of Partial Replacement of Palm Oil with Schizochytrium Oil on Rumen Microbiota, Ruminal Volatile Fatty Acid Concentrations, Rumen Epithelial Transcriptome, and Serum Metabolome in Hu Lambs Fed a Medium-Fiber Diet.

Yao Rongyu R, Wang Ziang Z, Weng Xiuxiu X, Yue Xiangpeng X et al.

Schizochytrium oil (SO) is rich in docosahexaenoic acid (DHA), but its ruminal effects in sheep remain unclear. Twenty Hu lambs were fed CK or SO diets for 84 d. The CK diet contained 4% palm oil, 31.43% neutral detergent fiber (NDF), and 5.58% ether extract (EE). The SO diet contained 3% palm oil and 1% SO, with similar NDF (31.76%) and EE (5.45%). Blood samples were collected one day before slaughter, before the morning feed replenishment, whereas rumen contents and epithelial tissue were collected after slaughter following a 16-h fast. Rumen microbiota, volatile fatty acids (VFAs), epithelial morphology (n = 10/group), RNA-seq (n = 4/group), and serum metabolomics (n = 5/group) were analyzed. The results showed that the rumen microbial community structure did not differ between the two groups (PERMANOVA, R2 = 0.101, p > 0.05), but SO selectively altered the relative abundance of seven genera (FDR < 0.05), including higher Fibrobacter and lower Methanosphaera. These changes were accompanied by higher acetate, propionate, butyrate, valerate, and total VFA concentrations and a lower acetate/propionate ratio (p < 0.05). Histological analysis showed that rumen papilla length and total epithelial thickness were higher in the SO group than in the CK group (2286.49 vs. 1764.30 μm and 114.52 vs. 80.07 μm, respectively; p < 0.05). Rumen epithelial RNA-seq showed enrichment of pathways related to VFA metabolism, energy metabolism, and fatty acid metabolism in the SO group (FDR < 0.01). Serum metabolomics showed higher levels of DHA and several DHA-containing lipids in the SO group (FDR < 0.05). Overall, partial replacement of palm oil with 1% SO selectively altered selected rumen genera and increased ruminal propionate concentration, accompanied by changes in rumen epithelial morphology and metabolism and increased serum DHA-related lipids. These findings support the potential of SO as a dietary DHA source for Hu lambs and provide evidence for its effects on the rumen and serum DHA-related lipid profile.

PMID 42943507
阅读全文 →
PubMedJAAPA : official journal of the American Academy of Physician Assistants2026-10-27

Atopic dermatitis.

Hulsey Brittney B, Walker Clay W CW, McFarlane Amanda A

Atopic dermatitis (AD) is a chronic, relapsing inflammatory skin disease that commonly begins in childhood and can persist or first appear in adulthood. Its burden reflects pruritus, sleep loss, pain, infection, psychosocial effects, and treatment demands rather than visible extent alone. Diagnosis is clinical and requires recognition of age- and skin tone-specific morphology and exclusion of mimics. AD management begins with moisturization, gentle bathing, topical anti-inflammatory therapy, education, and proactive maintenance. Newer nonsteroidal topical agents and targeted systemic therapies have expanded options, but treatment should be individualized according to age, disease severity and control, comorbidities, safety, access, and patient preference. Routine elimination diets, topical antimicrobials for uninfected disease, antihistamines as primary antipruritic therapy, and systemic corticosteroids are generally not recommended for AD. This review provides physician associates with a practical approach to diagnosis, severity assessment, stepwise treatment, complication recognition, and timely referral.

PMID 42934910
阅读全文 →

注册免费账户还可查看另外 9996 篇文献

免费注册查看全部文献 →

了解更多fluticasone propionate